Moderna stock rises 5.6 percent on melanoma data

Moderna Inc. (ISIN US60770K1079) reached USD 183.08 on Nasdaq on September 23, 2026, marking a 5.6 percent gain from the previous close of USD 172.94. The move brought the stock to its reported 52-week high as investors assessed new melanoma vaccine data.

Melanoma data drive the move

Three research abstracts on Moderna's intismeran autogene were accepted for presentation at the European Society for Medical Oncology Congress 2026 in Madrid from October 23 to October 27, according to BigGo Finance on September 22, 2026. The abstracts concern a Phase 3 melanoma program being developed with Merck and Co, making the October data presentation the next major clinical checkpoint.

The market reaction was substantial: Moderna shares rose 5.6 percent to USD 182.56 at the September 22 close, while volume reached 23,758,405 shares, 101 percent above the average session volume of 11,791,728 shares, according to MarketBeat on September 22, 2026.

Revenue beats the quarterly forecast

Moderna reported second-quarter 2026 revenue of USD 145.00 million and earnings of negative USD 1.97 per share, according to MarketBeat on September 22, 2026. Revenue exceeded the USD 102.93 million consensus estimate by USD 42.07 million, while EPS beat the negative USD 2.03 estimate by USD 0.06. Revenue was 2.1 percent higher than in the same quarter of 2025, although the company remained loss-making.

The financial contrast matters for the stock. Clinical optimism has lifted the market value to USD 61.50 billion as of September 23, 2026, while the latest reported quarter still showed negative earnings. MarketBeat also cited a negative net margin of 141.43 percent for the reported period, underscoring the distance between pipeline expectations and current profitability.

Stock reaches a new yearly high

Moderna traded between USD 22.36 and USD 183.08 over the 52-week period reported on September 23, 2026. The latest price therefore stood at the top of that range, while reported volume reached 20,238,545 shares and market capitalization stood at USD 61.50 billion.

The next evidence investors will receive is clinical rather than financial: the ESMO Congress presentation scheduled for October 23 through October 27, 2026. Until then, the stock's valuation remains tied to whether the melanoma program can translate promising research visibility into detailed clinical results.

Moderna stock closes near its high

Moderna stock stood at USD 183.08 on Nasdaq as of September 23, 2026, with a 52-week range of USD 22.36 to USD 183.08 and a market capitalization of USD 61.50 billion.

More news and analyses on Moderna stock